USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS
申请人:Axovant Sciences GmbH
公开号:US20210128528A1
公开(公告)日:2021-05-06
Disclosed herein are methods of using a 5-HT
2A
serotonin receptor inverse agonist for the prophylaxis and/or treatment of psychosis or psychotic symptoms in an individual comprising administering to said individual in need thereof a therapeutically effective amount of said 5-HT
2A
serotonin receptor inverse agonist.